Sign up USA
Proactive Investors - Run By Investors For Investors

GTx reveals pre-clinical success for potential SUI treatment

GTx showed it could increase pelvic floor muscle mass and ‘turn off’ genes associated with muscle degradation.
GTx reveals pre-clinical success for potential SUI treatment
GTx is evaluating an orally administered treatment for postmenopausal women

GTx Inc (NASDAQ:GTXI) has told investors it has shown that its technology can increase pelvic floor muscle mass and ‘turn off’ genes associated with muscle degradation.

A Phase 2 proof-of-concept clinical trial is currently being conducted for postmenopausal women with stress urinary incontinence (SUI), though today’s data is from a preclinical study, modelled using animals.

This study approximates the pelvic floor changes that can be associated with SUI, the company said.

Two of the company’s elective androgen receptor modulators (SARMs) - GTx-024 (enobosarm) and GTx-027 - were used in the study in a mouse model.

“These results demonstrate the ability of these SARMs to restore the pelvic floor muscles to their normal weight and provide support for a potential role of these compounds in the treatment of SUI,” said Dr Ramesh Narayanan, who is acting as consultant to GTx.

The result is being presented today in New Orleans, at a meeting of the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU).

In its ongoing Phase 2 trial, GTx is evaluating the effects of orally administered enobosarm.

View full GTXI profile View Profile

GTx Timeline

Related Articles

GW_Pharma.png
June 07 2017
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy
picture of drug lab
February 07 2017
Amryt Pharma’s strategy to acquire, in-license and then develop drugs for hard to treat, so-called orphan diseases has been seeing some good progress.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use